Cancer-Associated Venous Thromboembolism-Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline

Research output: Contribution to journalResearch articleContributedpeer-review


  • Hanno Riess - , Aarhus University (Author)
  • Jan Beyer-Westendorf - , Department of internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Uwe Pelzer - , Aarhus University (Author)
  • Robert Klamroth - , Vivantes Hospitals Berlin (Author)
  • Birgit Linnemann - , University Medical Center Mainz (Author)


Patients with cancer are prone to develop venous thromboembolism (VTE) with negative impact on quality of life, morbidity, and mortality. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE (CAT) basically comprises initial and maintenance treatment, for 3 to 6 months, secondary preventions, and treatment in special situations. Therapeutic anticoagulation is the treatment of choice in CAT. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that had been recommended for decades, direct oral anti-factor Xa inhibitors, a subgroup of direct oral anticoagulants (DOACs), demonstrated their advantages along with the accompanying concerns in several randomized controlled treatment trials of CAT. The latest guidelines, such as the German AWMF-S2k Guideline "Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism," agree with each other on most aspects with respect to the treatment of CAT. Encompassing recent clinical studies, and meta-analyses, as well as the focus on some special management aspects of CAT, the objective of this review is to present a current overview and recommendations for the treatment of CAT.


Original languageEnglish
Publication statusE-pub ahead of print - 22 Nov 2023

External IDs

Scopus 85178158831


Sustainable Development Goals